Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 886 to 900 of 1422 results for social care

  1. Guide to the technology appraisal and highly specialised technologies appeal process (PMG41)

    Guide to the technology appraisal and highly specialised technologies appeal process

  2. Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)

    Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.

  3. Supporting young people to manage their conditions:- What is the relationship between transition and subsequent self-management?

    from children's to adults' services for young people using health or social care services Number NG43 Date issued February 2016

  4. Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)

    Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.

  5. Holistic assessment in the community:- What is the clinical and cost effectiveness of a community holistic assessment and intervention for people living with high levels of multimorbidity?

    are relevant to patients and health and social care services (for example, quality of life, hospital and care home...

  6. Transition support for young adults:- What approaches to providing transition support for those who move from child to adult services are effective and/or cost-effective?

    from children's to adults' services for young people using health or social care services Number NG43 Date issued February 2016

  7. Brodalumab for treating moderate to severe plaque psoriasis (TA511)

    Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.

  8. Management of inflammatory arthritis

    were previously only recommended for severe RA . Organisation of care We recommend that adults with RA or SpA should have ongoing access...

  9. Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine (TA928)

    Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.

  10. Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) with cyclophosphamide, doxorubicin and prednisone for untreated systemic anaplastic large cell lymphoma in adults.

  11. Ivabradine for treating chronic heart failure (TA267)

    Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.

  12. Artificial intelligence technologies to aid contouring for radiotherapy treatment planning: early value assessment (HTE11)

    Early value assessment (EVA) guidance on artificial intelligence technologies to aid contouring for radiotherapy treatment planning in people having external be...

  13. Dupilumab for treating severe asthma with type 2 inflammation (TA751)

    Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.

  14. Needle-free arterial non-injectable connector (MIB85)

    NICE has developed a medtech innovation briefing (MIB) on the needle-free arterial non-injectable connector .

  15. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.